KEGG   DISEASE: Ovarian cancerHelp
Entry
H00027                      Disease                                

Name
Ovarian cancer
Description
Ovarian cancer is the sixth most common cancer and the fifth leading cause of cancer-related death among women in developed countries. Approximately 90% of human ovarian cancer arises within the ovarian surface epithelium (OSE), with the rest originating from granulosa cells or, rarely, stroma or germ cells. Ovarian epithelial tumors are divided into mucinous, serous, endometrioid, and clear cell subtypes. Approximately 10% of ovarian cancers arise in women who have inherited mutations in cancer susceptibility genes (BRCA1 or BRCA2). The vast majority of ovarian cancers are sporadic, resulting from the accumulation of genetic damage over a lifetime. Several specific genes involved in ovarian carcinogenesis have been identified, including the p53 tumor suppressor gene and ERBB2 and PIK3CA oncogenes.
Category
Cancer
Brite
Human diseases [BR:br08402]
 Cancers
  Cancers of the breast and female genital organs
   H00027  Ovarian cancer
Human diseases in ICD-11 classification [BR:br08403]
 02 Neoplasms
  Malignant neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues
   Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues
    Malignant neoplasms of female genital organs
     2C73  Malignant neoplasms of ovary
      H00027  Ovarian cancer
Tumor markers [br08442.html]
 H00027
Cancer-accociated carbohydrates [br08441.html]
 H00027
BRITE hierarchy
Pathway
hsa05206  MicroRNAs in cancer
Gene
BRCA1 (germline mutation / deletion) [HSA:672] [KO:K10605]
BRCA2 (germline mutation / deletion) [HSA:675] [KO:K08775]
MSH2 (germline mutation) [HSA:4436] [KO:K08735]
MLH1 (germline mutation) [HSA:4292] [KO:K08734]
ERBB2 (amplification / overexpression) [HSA:2064] [KO:K05083]
K-ras (mutation) [HSA:3845] [KO:K07827]
AKT2 (amplification) [HSA:208] [KO:K04456]
PIK3CA (amplification) [HSA:5290] [KO:K00922]
c-MYC (overexpression) [HSA:4609] [KO:K04377]
p53 (mutation / deletion, overexpression) [HSA:7157] [KO:K04451]
Drug
Cyclophosphamide [DR:D00287]
Melphalan [DR:D00369]
Thiotepa [DR:D00583]
Gemcitabine hydrochloride [DR:D01155]
Paclitaxel [DR:D00491]
Doxorubicin hydrochloride [DR:D01275]
Cisplatin [DR:D00275]
Carboplatin [DR:D01363]
Bevacizumab [DR:D06409]
Altretamine [DR:D02841]
Hydroxyurea [DR:D00341]
Topotecan hydrochloride [DR:D02168]
Olaparib [DR:D09730] (BRCA-mutated)
Niraparib [DR:D10140]
Rucaparib [DR:D10079] (BRCA-mutated)
Comment
ICD-O: 8441/3, Tumor type: Adenocarcinoma
ICD-O: 8480/3, Tumor type: Adenocarcinoma
ICD-O: 8380/3, Tumor type: Adenocarcinoma, not otherwise specified
ICD-O: 8310/3, Tumor type: Adenocarcinoma
ICD-O: 9000/3, Tumor type: Malignant Brenner tumor
Other DBs
ICD-11: 2C73
ICD-10: C56
MeSH: D010051
Reference
PMID:15111296 (tumor type)
  Authors
Shih IeM, Kurman RJ.
  Title
Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.
  Journal
Am J Pathol 164:1511-8 (2004)
DOI:10.1016/S0002-9440(10)63708-X
Reference
PMID:12886939 (gene, tumor type)
  Authors
Katabuchi H, Okamura H.
  Title
Cell biology of human ovarian surface epithelial cells and ovarian carcinogenesis.
  Journal
Med Electron Microsc 36:74-86 (2003)
Reference
  Authors
Wenham RM, Lancaster JM, Berchuck A.
  Title
Molecular aspects of ovarian cancer.
  Journal
Best Pract Res Clin Obstet Gynaecol 16:483-97 (2002)
DOI:10.1053/beog.2002.0298

» Japanese version

DBGET integrated database retrieval system